Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duodart versus watchful waiting with step-up tamsulosin in treatment-naive men with moderately symptomatic benign prostatic hyperplasia
2010-022111-19Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alpha blocker + 5-alpha reductase inhibitor and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoint: Change in International Prostate Symptom Score. Started Sep 2010; status: completed.
02
Drugs
alpha blocker + 5-alpha reductase inhibitortamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2010-022111-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022111-19.